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Abstract 
 
Reactive oxygen species (ROS) are major exacerbation factor in acute ischemic stroke, and 
thrombolytic agent tissue plasminogen activator (tPA) may worsen motor function and cerebral 
infarcts. The platinum nanoparticle (nPt) is a novel ROS scavenger, and thus we examined the 
clinical and neuroprotective effects of nPt in ischemic mouse brains. Mice were subjected to 
transient middle cerebral artery occlusion (tMCAO) for 60 min and divided into the following 
four groups by intravenous administration upon reperfusion, vehicle, tPA, tPA+nPt, and nPt. At 
48 hrs after tMCAO, motor function, infarct volume, immunohistochemical analyses of 
neurovascular unit (NVU), in vivo imaging of matrix metalloproteinase (MMP), and 
zymography for MMP-9 activity were examined. Superoxide anion generation at 2 hrs after 
tMCAO was also examined with hydroethidine. As a result, administration of tPA deteriorated 
the motor function and infarct volume as compared to vehicle. In vivo optical imaging of MMP 
showed strong fluorescent signals in affected regions of tMCAO groups. Immunohistochemical 
analyses revealed that tMCAO resulted in a minimal decrease of NAGO and occludin, but a 
great decrease of collagen IV and a remarkable increase of MMP-9. Hydroethidine stain showed 
increased ROS generation by tMCAO. All these results became pronounced with tPA 
administration, and were greatly reduced by nPt. The present study demonstrates that nPt 
treatment ameliorates neurological function and brain damage in acute cerebral infarction with 
neuroprotective effect on NVU and inactivation of MMP-9. The strong reduction of ROS 
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production by nPt could account for these remarkable neurological and neuroprotective effects 
against ischemic stroke. 
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1. Introduction 
 
Acute ischemic stroke is a major cause of death and, even when not fatal, usually results in 
permanent neurological impairments, for which both blood flow improvement and 
neuroprotective therapies are critical. A thrombolytic agent, tissue plasminogen activator (tPA), 
has been used for the treatment of acute cerebral infarction, but its application is limited due to 
the narrow therapeutic time window and side effect of hemorrhagic transformation (Tsirka et al., 
1995; Wang et al., 1998; Nagai et al., 1999; Kilic et al., 2005; Ning et al., 2006; Yamashita et al., 
2009; Abu et al., 2010). Intravenous tPA treatment has been limited to within 3 hrs after the onset 
of ischemic stroke, but recent clinical evidence provided an extension of the time window from 3 
to 4.5 hrs (Wahlgren et al., 2008; Lansberg et al., 2009). However, the extension also increased 
the risk of hemorrhagic complications (Wahlgren et al., 2008; Lansberg et al., 2009), which 
further increases the demand for neuroprotection to reduce the risk of harmful cerebral 
hemorrhage. 
The generation of reactive oxygen species (ROS) starts soon after vessel occlusion and 
propagates explosively after reperfusion (Chan, 2001). These ROS have been proved to be of key 
importance in the pathogenesis of ischemic brain injury (Kinouchi et al., 1991; Kontos, 2001). 
We originally reported that a free radical scavenger edaravone strongly ameliorated edema in the 
ischemic brain (Abe et al., 1988) and reduced the infarct size and free radical end products of 
lipids, proteins, and DNA (Zhang et al., 2004). Because edaravone strongly improved the 
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disability after ischemic stroke without serious adverse events (The Edaravone Acute Brain 
Infarction Study group, 2003), it has been used in clinical therapy for ischemic stroke in Japan 
from 2001. We have furthermore reported the strong neuroprotective effect of edaravone 
especially in preserving neurovascular units (NVU) after cerebral ischemia in the stroke-prone 
spontaneously hypertensive rat (Yamashita et al., 2009). Besides edaravone, we have also 
reported that ischemic brain damage was ameliorated by other neuroprotective substrates such as 
HMG-CoA reductase inhibitor statins (Hayashi et al., 2005; Nagotani et al., 2005), 
antihypertensive azelnidipine (Lukic-Panin et al., 2007), and biliverdin (Deguchi et al., 2008) 
after ischemic stroke. 
Platinum nanoparticle (nPt) species have been reported as novel free radical scavengers 
which strongly ameliorate oxidative damage in vitro and in vivo (Kim et al., 2008, 2010; 
Onizawa et al., 2009; Watanabe et al., 2009; Sakaue et al., 2010; Takamiya et al., 2011). Due to 
the larger surface area-to-volume ratio of smaller particles, nPt can potentiate the catalytic 
activity of metals, and its colloidal forms contribute to a further efficient catalysis with high 
electron holding at the surface (Roucoux et al., 2002), allowing it to quench both superoxide 
anion and hydrogen peroxide (Kajita et al., 2007; Hamasaki et al., 2008). We have previously 
reported that administration of nPt could be beneficial for clinical improvement and 
neuroprotection in the pathological aspects of mice after transient middle cerebral artery 
occlusion (tMCAO) (Takamiya et al., 2011), and in the present study, we further investigated the 
efficacy of nPt associated with tPA administration. 
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2. Experimental procedures 
2.1.1. Animal model 
Male C57/Bl6 mice (Japan SLC Inc, Shizuoka, Japan, 8 weeks old, weighing 24-27 g) 
were anesthetized with an nitrousoxide/oxygen/isofluran mixture (69: 30: 1%) during surgical 
preparation. tMCAO was induced by the intraluminal filament technique according to our 
previous report (Lukic-Panin et al., 2007; Abe et al., 1992; Yamashita et al., 2006). In brief, the 
right common carotid artery was isolated and a small incision was made for thread insertion. 
Then, 8-0 nylon thread with a silicon-coated tip was inserted into the right MCA and gently 
advanced 9.0-10.0 mm to occlude the origin of MCA. During these surgical treatments and 
subsequent ischemic period, body temperature was monitored to maintain a temperature of 37 ± 
0.3°C by placing animals on a heating bed (Model BWT-100; Bio Research Center, Nagoya, 
Japan). Regional CBF in the ischemic area was estimated by measuring blood flow at partial 
resection of the scalp 1 mm posterior and 3 mm lateral to the bregma with a laser-Doppler flow 
meter (FLO-C1; Omegawave, Tokyo, Japan). CBF was monitored at a baseline time point before 
the ischemic operation, at 5 and 10 min after the cerebral ischemia, and at 5 min after the 
reperfusion, as described in our previous reports (Lukic-Panin et al., 2007; Yamashita et al., 
2006). At 60 min after tMCAO, the nylon thread was withdrawn for reperfusion, followed by 
intravenous administration of the drug as described below in detail. After the incision was closed, 
the animals recovered and were allowed free access to water and food at an ambient temperature 
(21-23°C) until motor function evaluation, in vivo imaging, and subsequent brain sampling for 
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ex vivo imaging, infarction volume determination, zymography, and immunohistochemistry. The 
experimental protocol and procedure were approved by the Animal Committee of the Graduate 
School of Medicine and Dentistry, Okayama University. 
 
2.1.2. Preparation and administration of drug and 5 mice groups 
      The nPts were prepared by ethanol reduction of H2PtCl6・ 6H2O as described previously 
(Kim et al., 2008). Poly (N-vinyl-2-pyrrolidone) was used as a protecting reagent to prepare an 
evenly dispersed suspension. The nPts were dissolved in physiological saline (PS) and stored at 
4°C until use.    
     The mice were divided into 5 groups, the sham control group receiving only a surgical 
sham operation without thread insertion (total n=12: 3 for motor function assessment with 
subsequent infarction volume determination and immunohistochemistry, 3 for in vivo and ex 
vivo optical imaging of MMP, 3 for zymography, and 3 for detection of superoxide anion), the 
tMCAO-vehicle group receiving only a vehicle (PS administered from tail vein at 10 mL/kg of 
mouse) at the time of reperfusion after 60 min of tMCAO (total n=21: 12, 3, 3, and 3), the 
tMCAO-tPA (Alteplase, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, intravenously, 
10mg/kg) group receiving tPA at reperfusion (total n=17: 8, 3, 3, and 3), tMCAO-tPA+nPt group 
receiving nPts (4.0 μmol/kg of mouse) just after tPA administration at reperfusion (total n=17: 8, 
3, 3, and 3), and tMCAO-nPt group receiving nPts at reperfusion (total n=19: 10, 3, 3, and 3). 
The administration volume of each group was approximately 0.3 ml according to the weight of 
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the mice. 
 
2.2.1. Behavioral analysis 
  At 48 hrs after the reperfusion, the mice were evaluated by behavioral tests as described by 
Bederson (Bederson et al., 1986) with our minor modifications (Yamashita et al., 2009) as 
follows: 0, no observable neurologic deficits; 1, failure to extend the right forepaw; 2, circling to 
the contralateral side; 3, falling to the right; 4, unable to walk spontaneously. After Bederson's 
test, a rota-rod test (MK-610A, MUROMACHI KIKAI CO., LTD) was performed 3 times with 
an accelerating spindle speed from 5 to 45 rpm over a period of 1 min. The scoring was carried 
out blind to each condition.  
 
2.2.2. Measurement of infarct volume 
     After finishing behavioral analysis, the mice were anesthetized again by intraperitoneal 
injection of pentobarbital (40 mg/kg), and transcardially perfused with chilled 5 U/ml heparin in 
phosphate-bufferd saline (PBS), followed by 4% paraformaldehyde in 0.1 M sodium phosphate 
buffer (pH 7.4). Subsequently, brains were removed, immersed with 4% paraformaldehyde in 
PBS over night at 4,°C and subjected to consecutive incubation with 10, 20 and 30% sucrose in 
PBS. Each sucrose incubation step was for 24 hrs at 4°C. Then, the treated brains were rapidly 
frozen in dry ice for preparation of 20 μm thick coronal sections at the caudate level with a 
cryostat maintained at -20°C. The sliced sections were mounted on silane-coated slide glasses.  
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Coronal brain sections of these mice were stained with HE to quantify infarct volume with 
a standard computer-assisted image analysis technique. The total infarct volume of the cerebral 
cortex or CPu for each brain was calculated by summation of the infarcted area of 7 serial brain 
slices, at a 500 μm interval each, between 1.0 mm anterior, and 2.0 mm posterior, to the bregma. 
To eliminate the contribution of postischemic edema, infarct volume measurements were 
corrected as previously described (Kitano et al., 2004). 
 
2.3.1. In vivo optical imaging of matrix metalloproteinase  
Mice were subjected to in vivo imaging at 48 hrs after the tMCAO. The fluorescent 
compound MMPSense 680 (VisEn Medical Inc., USA) was used in this experiment for testing 
matrix metalloproteinases (MMPs including MMP-2, -3, the key -9 and -13). MMPSense (300 μl) 
was intravenously injected 12 hrs before the in vivo imaging (i.e., 36 h after tMCAO). For in 
vivo imaging, the mice were anesthetized with a nitrous oxide/oxygen/isoflurane mixture 
(69/30/1%) administered through an inhalation mask, and the near-infrared fluorescence (NIRF) 
images were observed by a macro fluorescence imaging system as described above with or 
without the head skin.  
For in vivo imaging, we used the macro fluorescence imaging system MVX 10 Macro 
View (Olympus, Japan). For excitation of fluorescent compounds, an intensity-controlled laser 
diode emitting at 682 nm was used. The fluorescence emission at 721 nm was collected by a 
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charge-coupled device (CCD) camera (Digital camera C10600 ORCA-R2, Hamamatsu, Japan) 
with an acquisition time of 3.0 sec. The transillumination fluorescence images (TFI) were 
analyzed by MetaMorph Version 7.5 image analysis software. 
     
2.3.2. Ex vivo optical imaging of matrix metalloproteinase 
After taking in vivo images, the mouse brains were removed under deep anesthesia with 
pentobarbital (40 mg/kg, i.p.), and ex vivo imaging for MMP was quickly performed as above. 
Just after ex vivo imaging of the tMCAO-tPA-treated mouse brains, immunofluorescent staining 
of MMP-9 was performed with the primary antibody for MMP-9 (1:200; R&D SYSTEMS, 
Minnesota) and secondary antibody conjugated with Alexa Fluor 488 (1:500; Invitrogen, CA) to 
confirm that the fluorescence actually represents MMP. Using another set of tMCAO-tPA treated 
mice (n=3), TTC stain was also performed after obtaining ex vivo images with MMPSense.  
 
2.4. Immunohistochemistry 
     As described above, coronal brain sections of 20 μm thickness at the caudate level were 
cut and mounted on silane-coated slide glasses. The sections were first washed in PBS and then 
incubated with 30% methanol and 0.3% hydrogen peroxide in PBS in order to quench 
endogenous peroxide activity. After non-specific reactions were blocked by 5% bovine serum 
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albumin (BSA) in PBS for 1 hr, the slides were incubated overnight at 4°C with the primary 
antibody in 5% BSA in PBS. Then, the slides were washed in PBS and incubated for 1 hr with an 
appropriate biotin-labeled secondary antibody (1:500) at room temperature. They were 
subsequently incubated with an avidin-biotin-peroxide complex (Vector Laboratories, 
Burlingame, CA) for 30 min and the signal was visualized with diaminobenzidine 
tetrahydrochloride. The primary antibodies in this study were as follows: anti-MMP-9 (1:200; 
R&D SYSTEMS, Minnesota), anti-collagen IV (1:100; NOVOTEC, Lyon, France), 
anti-occludin (1:100; SANTA CRUZ Biotechnology, CA), and NAGO (1:200; Vector 
Laboratories, Burlingame, CA). In each study, sections were stained in a similar way without the 
primary antibody as a negative control. 
 
2.5. Gelatine zymography 
At 48 hrs after reperfusion, mice were anesthetized by intraperitoneal injection of 
pentobarbital (40 mg/kg) and transcardially perfused with chilled 5 U/ml heparin in PBS. Brains 
were removed quickly and divided into ipsilateral-ischemic and contralateral-nonischemic 
hemispheres. Each hemispheric brain was frozen immediately in dry ice and stored at -80°C until 
use. 
Brain samples were homogenized in a 10 × volume lysis buffer (150 mM NaCl, 1% SDS, 
0.1% deoxycholic acid, and 50 mM Tris-HCl, pH 7.4) containing protease inhibitors. After 
centrifugation at 9,000 × g for 15 min at 4°C, the supernatant was collected. The total protein 
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concentration of each supernatant sample was spectrophotometrically determined using the 
Bradford assay (Ultrospec 3100 pro, GE Healthcare, Tokyo, Japan). The MMP-9 activity of each 
sample was measured using a gelatin-zymography kit (Primary cell, Sapporo, Japan) according 
to the manufacturer's instructions. In brief, each sample containing 20 μg protein was diluted 
with the homogenizing buffer in the kit, mixed with an equal volume of sample buffer, and 
loaded for the electrophoresis for 2 hrs. The gels were washed and incubated for 24 hrs with the 
incubation buffer at 37°C. The gels were stained with Coomassie blue and scanned. Quantitative 
densitometric analysis was performed using ImageJ software. 
 
2.6. Detection of superoxide anions (SA) and double immunofluorescent analysis 
     Production of SA in the mouse brains after 60 min of tMCAO was investigated by in situ 
detection with oxidized hydroethidine (HEt) as described previously (Sugawara et al., 2002). 
Intravenously-administered HEt (Molecular Probes, Eugene, OR) is taken up by living cells and 
oxidized by SA to produce a red fluorescent dye, ethidium (Bindokas et al., 1996). In the present 
experiment, 0.1 ml of 1 mg/ml HEt in PS containing 1% dimethylsulfoxide was administered via 
the tail vein at 60 min after tMCAO. At 60 min after the drug administration, mice were 
anesthetized by intraperitoneal injection of pentobarbital (40 mg/kg) and transcardially perfused 
with chilled 5 U/ml heparin in PBS, followed by 4% paraformaldehyde in 0.1 M phosphate 
buffer (pH 7.4). The brains were then removed, immersed with 4% paraformaldehyde in PBS 
overnight at 4°C, and rapidly frozen in dry ice. Twenty micrometer thick coronal sections were 
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cut at the caudate level with a cryostat kept at -20°C and mounted on silane-coated slide glasses.  
     Immunofluorescent analysis was performed to investigate the ROS-production level of 
each cell component constituting brain tissue. The sections were first washed in PBS and after 
non-specific reactions were blocked by 5% BSA in PBS for 1 hr, the slides were incubated 
overnight at 4°C with the primary antibody in 5% BSA in PBS. The slides were then washed in 
PBS and incubated for 1 hr with an appropriate secondary antibody at room temperature. The 
primary antibodies in this study were as follows: anti-CD31 (1:50; BD Biosciences, CA) for 
endothelium, anti-MAP2 (1:200; MILLIPORE, CA) for neuron, anti-GFAP (1:200; Glostrup, 
Denmark) for astrocyte, and anti-IBA1 (1:200; Wako Pure Chemical Industries, Osaka, Japan) 
for microglia. In each study, sections were stained in a similar way without the primary antibody 
as a negative control. The secondary antibodies were as follows: Alexa Fluor 350 (1:500; 
Invitrogen, CA) for anti-CD31 antibody, and Alexa Fluor 488 (1:500;Invitrogen, CA) for 
anti-MAP2, -GFAP, -IBA1 antibodies, respectively. The slides were covered with 
VECTASHIELD mounting medium (Vector Laboratories, Burlingame, CA) and the 
peri-infarction areas were observed with a fluorescence stereomicroscope (Olympus 
FLUOVIEW FV10i; Olympus Optical Co., Tokyo, Japan). The mean signal intensity randomly 
chosen in 10 fields of peri-infarction area were quantified using computer software MetaMorph® 
(Molecular Devices Corporation, Sunnyvale, CA). The data of mean signal intensity are 
presented as Unit/area. We have quantified the Ethidium fluorescence ratiometrically as follows. 
First semiquantitative fluorescence were measured in the anatomically comparable sites of 
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contralateral hemisphere with the peri-infarct region of ipsilateral hemisphere by calculating the 
sum of integral intensity using the image analysis software, then we confirmed that there were no 
significant difference in the fluorescent signal intensity between sham control and each tMCAO 
groups. Subsequently integral fluorescent signal intensity of contralateral site comparable to 
peri-infarct region of ipsilateral hemisphere were hence subtracted to correct for background. 
 
2.7. Statistical analysis 
Results are presented as the mean ± standard deviation (SD). Statistical comparisons were 
conducted using Mann-Whitney tests followed by Kruskal-Wallis tests for intergroup 
comparisons. A probability value of p < 0.05 was considered statistically significant. 
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3. Results 
3.1. Cerebral blood flow (CBF) 
     After tMCAO, CBF immediately dropped to less than 30% of the baseline. With 
reperfusion, CBF quickly recovered to the basal level in all groups (i.e. tMCAO-vehicle, 
tMCAO-tPA, tMCAO-tPA+nPt and tMCAO-nPt groups). Throughout these tMCAO experiments, 
there was no significant difference in CBF between all groups (data not shown). 
 
3.2. Motor function and infarct volume 
     To evaluate motor function in the mice at 48 hrs after 60 min of tMCAO, Bederson's and 
rota-rod tests were performed. Bederson's grades of the sham control, tMCAO-vehicle, 
tMCAO-tPA, tMCAO-tPA+nPt, and tMCAO-nPt groups were 0 ± 0 (mean ± standard deviation), 
2.17 ± 0.39⋆⋆, 2.38 ± 0.52⋆⋆, 1.63 ± 0.52⋆⋆,*,# and 1.10 ± 0.57⋆⋆,**, respectively (⋆⋆p < 0.01 vs 
sham control group, *p < 0.05, **p < 0.01 vs tMCAO-vehicle group, #p < 0.05 vs tMCAO-tPA 
group; Fig. 1A). Rota-rod scores of the above 5 groups were 44.3 ± 15.3 (sec), 17.3 ± 5.4⋆⋆, 11.9 
± 3.8⋆⋆,*, 21.7 ± 8.5⋆⋆,#, and 29.9 ± 9.0  ,**, respectively (⋆⋆p < 0.01 vs sham control group, *p < 
0.05, **p < 0.01 vs tMCAO-vehicle group, #p < 0.05 vs tMCAO-tPA group; Fig. 1B).  
     Hematoxyline-eosin (HE) -stained sections at 48 hrs after 60 min of tMCAO showed that 
the infarct volumes at the cerebral cortex in the tMCAO-vehicle and -nPt groups were 30.1 ± 5.2 
(mm3), 38.2 ± 5.7**, 22.1 ± 6.3*,##, and 17.3 ± 6.8** (*p < 0.05, **p < 0.01 vs tMCAO-vehicle 
group, ##p < 0.01 vs MCAO-tPA group), and at the caudoputamen (CPu) were 9.2 ± 1.3, 9.2 ± 
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0.9, 7.5 ± 1.5*,# and 7.3 ± 1.2** (p = n.s.), respectively (*p < 0.05, **p < 0.01 vs 
tMCAO-vehicle group, #p < 0.05 vs MCAO-tPA group) (Fig. 1C). 
 
3.3. In vivo and ex vivo optical imaging of matrix metalloproteinase 
     The in vivo fluorescent optical signal of matrix metalloproteinase (MMP) was scarcely 
detected with scalp and hair, but became clearly detected through skull bone by removing the 
scalp. Fig. 2A demonstrates the in vivo optical image of MMP at 48 hrs after tMCAO by 
near-infrared fluorescence (NIRF) observation of fluorescent compounds using MMPSense 680 
(upper panels for non-fluorescence observation, and the lower panels for pseudocolor image). 
There was almost no fluorescence over the sham control head, but clear fluorescence was 
observed in the affected hemisphere reflecting the right middle cerebral artery (MCA) territory, 
with signal strength in the order tMCAO-tPA > tMCAO-vehicle > tMCAO-tPA+nPt > 
tMCAO-nPt group (Fig. 2A; lower panels). 
     Fig. 2B and 2C demonstrate the ex vivo imaging of MMP just after the in vivo imaging of 
the whole brain (Fig. 2B, upper panels for non-fluorescence observation and lower for 
pseudocolor image of MMPSense 680) and brain slice (Fig. 2C, similar to Fig. 2B). Compared 
with in vivo imaging (Fig. 2A), the fluorescent signal became more evident in the affected right 
MCA territory, with signal strength again in the order tMCAO-tPA > tMCAO-vehicle > 
tMCAO-tPA+nPt > tMCAO-nPt group (Fig. 2B and 2C; lower panels). 
     Macroscopic comparison of brain sections with TTC stain and ex vivo MMP images in 
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identical tMCAO-tPA mice showed close colocalization of 2,3,5-triphenyltetrazolium chloride 
(TTC) stain defect (white area, Fig. 2D) and MMP image increase (yellow area, Fig. 2D). 
Microscopic examination confirmed the colocalization of endogenous MMPSense signal and 
exogenous MMP-9 antibody in the affected area (Fig. 2E). 
 
3.4. Zymography for MMP-9 activity 
      There was only a trace level of MMP-9 activity in the sham control and contralateral 
brains of the tMCAO groups, which showed an evident increase in the ipsilateral hemisphere 
after tMCAO (Fig. 3A). As the reference of this sham control activity 1.00, relative ratio (RR) of 
the optical densities for MMP-9 in tMCAO-vehicle, tMCAO-tPA, tMCAO-tPA+nPt, and 
tMCAO-nPt in the contralateral hemisphere as 1.16 ± 0.40, 1.82 ± 1.01, 0.99 ± 1.00, and 1.20 ± 
0.40, respectively, and those in the ipsilateral hemisphere as 5.30 ± 0.88⋆, 7.84 ± 2.19⋆,*, 3.04 ± 
1.77⋆,# and 2.87 ± 0.45⋆,*, respectively (⋆p < 0.05 vs sham control group, *p < 0.05 vs 
tMCAO-vehicle group, #p < 0.05 vs tMCAO-tPA group) (Fig. 3B).  
 
3.5. Immunohistochemistry for NVU 
     Staining for NAGO exhibited short linear structures with a few branches in the peri-infarct 
area of cerebral cortex, representing the vascular endothelium (Fig. 4, top panels). The relative 
ratio (RR) of mean signal intensities for NAGO staining of the sham control group (as RR = 1), 
tMCAO-vehicle, tMCAO-tPA, tMCAO-tPA+nPt and tMCAO-nPt group were 1.00 ± 0.09, 0.72 
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± 0.14⋆⋆, 0.69 ± 0.07⋆⋆, 0.79 ± 0.26, and 0.81 ± 0.16⋆, respectively (⋆p < 0.05, ⋆⋆p < 0.01 vs 
sham control group).  
Staining for occludin also showed small linear structures with a few branches, representing 
the tight junction of neurovascular components (Fig. 4, second panels). The RR of signal 
intensities for occludin staining in these 5 groups were 1.00 ± 0.06, 0.72 ± 0.32⋆⋆, 0.70 ± 0.19⋆⋆, 
0.81 ± 0.29, and 0.86 ± 0.31, respectively (⋆⋆p < 0.01 vs sham control group). The signal 
intensity tended to be lower in the tMCAO-vehicle and tMCAO-tPA group, but again no 
significant difference was found. 
     Staining for collagen IV also showed linear structures with a few branches, clearly 
representing the basal lamina of neurovascular components (Fig. 4, third panels). The RR of 
signal intensities of collagen IV of the sham control, tMCAO-vehicle, tMCAO-tPA, 
tMCAO-tPA+nPt, and tMCAO-nPt groups were 1.00 ± 0.08, 0.58 ± 0.32⋆⋆, 0.30 ± 0.27⋆⋆, 0.74 ± 
0.23⋆,##, and 0.85 ± 0.14⋆,* (⋆p < 0.05, ⋆⋆p < 0.01 vs sham control group, *p < 0.05 vs 
tMCAO-vehicle group, ##p < 0.05 vs tMCAO-tPA group), respectively. Collagen IV was 
significantly degraded at 48 hrs after 60 min of tMCAO, which tended to be exacerbated by tPA 
administration, and these degradation were significantly salvaged by the nPt-treatment.  
     Staining for MMP-9 showed several shapes such as a similar linear structure to NAGO, 
occludin and collagen IV, and its surrounding small dots (Fig. 4, bottom panels), representing the 
extracellular matrix and possibly cells generating MMP-9 in the peri-infarct area. The RR of 
signal intensities for the MMP-9 of the sham control, tMCAO-vehicle, tMCAO-tPA, 
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tMCAO-tPA+nPt, and tMCAO-nPt groups were 1.00 ± 0.24, 5.28 ± 1.25⋆⋆, 9.97 ± 2.37⋆⋆,**, 4.03 
± 1.23⋆⋆,*,##, and 2.32 ± 0.34⋆⋆,** (⋆⋆p < 0.01 vs sham control group, *p < 0.05, **p < 0.01 vs 
tMCAO-vehicle group, ##p < 0.01 vs tMCAO-tPA group), respectively. MMP-9 staining was 
markedly increased at 48 hrs after tMCAO, which was exacerbated by tPA administration, and 
these marked increase were significantly inhibited by the nPt-treatment. 
     In all immunostainings above, no significant staining was found without a primary 
antibody, supporting the specific staining for each marker protein. 
 
3.6. Evaluation of superoxide production 
     Although no signal was detected in the sham control brain, the tMCAO-vehicle and 
tMCAO-tPA groups showed strong signals at the peri-infarct area in the ipsilateral cerebral 
cortex of the MCA territory. This signal was markedly reduced in the tMCAO-tPA+nPt and 
tMCAO-nPt groups (Fig. 5A). Statistical analysis of these signals showed that the RR of the 
signal intensities for superoxide of the sham control, tMCAO-vehicle, tMCAO-tPA, 
tMCAO-tPA+nPt, and tMCAO-nPt groups were 1.0 ± 0.4, 14.0 ± 6.6⋆⋆, 37.5 ± 12.2⋆⋆,**, 6.5 ± 
1.5⋆,#, and 2.6 ± 0.2⋆,*, respectively (⋆p < 0.05, ⋆⋆p < 0.01 vs sham control group, *p < 0.05, 
**p < 0.01 vs tMCAO-vehicle group, #p < 0.05 vs tMCAO-tPA group; Fig. 5A). Triple 
immunofluorescent analysis showed hydroethidine signals indicating the existence of superoxide 
predominantly in the endothelium (Fig. 5B, filled arrows) and at the peri-infarct area in the 
ipsilateral cerebral cortex of the MCA territory of tMCAO-vehicle and tMCAO-tPA groups with 
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less intensity with nPt treatments (Fig. 5B, open arrows). Small numbers of hydroethidine signals 
were also present in the outer margin of MAP2 fluorescence, suggesting a slight ROS production 
in the cytoplasmic membrane of peri-infarct neurons. The ROS production ratios of each cell 
component were as follows; the ratios of endothelium, neuron, microglia, and astrocyte were 
95.1%, 2.0%, 2.9% and 0%, respectively in sham control group, 44.6%, 39.4%, 12.7%, and 3.2% 
in tMCAO-vehicle group, 53.1%, 36.5%, 6.1%, and 4.1% in tMCAO-tPA group, 79.2%, 14.1%, 
1.7%, and 5.0% in tMCAO-tPA+nPt group, 94.1%, 2.0%, 2.8%, and 1.1% in tMCAO-nPt group, 
respectively (Fig. 5A). 
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4. Discussion 
The generation of ROS gradually increases during cerebral ischemia, but explosively 
increases after reperfusion especially in the ischemic penumbra oxidising the lipid, DNA and 
proteins (Chan, 1996; Morimoto et al., 1996; Peters et al., 1998; Abe, 2000; Cui et al., 2000; 
Zhang et al., 2001). Thus the detrimental effects of ROS in cerebral ischemia-reperfusion injury 
are profoundly associated with the pathophysiology of neural cell apoptosis and necrotic 
infarction (Demopoulos, 1973; Hayashi et al., 1999). We have previously demonstrated the 
strong neuroprotective effects of a free radical scavenger edaravone (Yamashita et al., 2009; Abe 
et al., 1988; Yoneda et al., 2003), which has been clinically used as the world's first 
neuroprotective drug in Japan since 2001. Recent evidence suggested that other free radical 
scavengers such as biliverdin (Deguchi et al., 2008), 6-hydroxy-2,5,7,8-tetramethylchroman-2- 
carboxylic acid (trolox) (Perfeito et al., 2007; Sharma and Kaundal, 2007) and 2,2,5,7,8- 
pentamethyl-6-hydroxychromane (PMC) (Hsiao et al., 2007) also ameliorated cerebral injury 
following experimental tMCAO.  
     In the present study, we took a novel free radical scavenger nPts because of its 
double-scavenging property for superoxide anion and hydrogen peroxide. The size of nPt, 
ranging from 2-3 nm, is the most potent subclass of antioxidant for application in living bodies. 
Unlike common antioxidants such as ascorbic acid which lose their reduction effect when 
oxidized, the antioxidative effect of nPt is durable for its feature as both SOD/catalase mimetic 
(Kajita et al., 2007; Hamasaki et al., 2008). In in vivo application, nPt extended the lifespan of 
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the roundworm Caenorhabditis ekegans (Kim et al., 2008, 2010; Sakaue et al., 2010), inhibited 
pulmonary inflammation in mice exposed to cigarette smoke (Onizawa et al., 2009), and 
inhibited cell growth of human tongue carcinoma cells (Saitoh et al., 2009). Furthermore we 
have previously reported that nPt ameliorates neurological function and brain damage after 
tMCAO in mice (Takamiya et al., 2011). The present study confirmed these findings and 
additionally showed that nPt ameliorated the exacerbated damage caused by tPA in conjunction 
with tMCAO in mice. 
      Large quantities of ROS are generated in the peri-vascular extracellular space after 
cerebral ischemia (Kontos et al., 1992). Such ROS are important for MMP-9 activation which 
participates in early blood-brain barrier (BBB) disruption triggered by oxidative stress generated 
during cerebral ischemia-reperfusion injury (Gasche et al., 2001; Kamada et al., 2007). Several 
experiments have demonstrated that early inhibition of MMP-9 significantly reduces the brain 
infarct size, indicating that MMP-9 is an important enzyme in contributing to focal ischemic 
brain injury (Yong et al., 2001; Tsuji et al., 2005, Klohs et al., 2009; Yagi et al., 2009). We 
previously reported that the free radical scavenger edaravone shows a protective effect on the 
NVU reducing MMP-9 activation after tMCAO of rats (Yamashita et al., 2009). Intravenous or 
intracerebral administration of tPA upregulates MMP-9 and exacerbates cerebral infarction 
through low-density lipoprotein receptor-related protein (Wang et al., 2003; Kilic et al., 2005; 
Tsuji et al., 2005; Machado et al., 2009; Yagi et al., 2009; Fanne et al., 2010; Lukic-Panin et al., 
2010). The present study demonstrated that administration of tPA at the time of reperfusion 
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significantly deteriorated the motor function of mice and increased infarct volume especially in 
the cerebral cortex, and that such clinical and pathological damage by tPA was significantly 
prevented by administration of nPt (Fig. 1). We further demonstrated that in vivo imaging of 
MMP activity was well correlated with MMP-9 activity and destruction of NVU after tMCAO, 
which was also ameliorated by nPt (Fig. 2-4). In the present study, the inner components of NVU 
such as NAGO and occludin were slightly damaged after tMCAO and administration of tPA as 
compared to stronger damage in the outer component collagen IV (Fig. 4), similar to our 
previous report (Yamashita et al., 2009). In the present study the site of ROS production after 
tMCAO and tPA administration was mainly the cerebrovascular endothelium and neurons, with a 
few in microglia and astrocytes (Fig. 5a). Both this ROS production and the preferential 
disruption of NVU were reduced by the present nPt treatment (Fig. 2-5), suggesting that nPt is a 
potential therapeutic option for ischemic stroke. The present study thus provides evidence for the 
therapeutic potential of new nPt with both SOD and catalase mimic activities for ischemic stroke 
patients with NVU protection to improve motor functions through strong antioxidative 
mechanisms. 
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Figure legends 
 
Figure 1. Neurobehavioral analysis and infarct volume 
     Quantitative analysis of (A) Bederson’s motor grade, (B) rota rod motor score, and (C) 
infarct volume at 48 hrs after tMCAO. Compared with the sham control group, the motor 
function of the tMCAO-vehicle group showed a strong reduction of motor scores (⋆⋆p < 0.01), 
with further exacerbation in the tMCAO-tPA group (*p < 0.05, **p < 0.01). Treatment with nPt 
showed a significant improvement (#p < 0.05, ##p < 0.01 tMCAO-tPA vs tMCAO-tPA+nPt 
group; *p < 0.05, **p < 0.01 vs tMCAO-vehicle group) (A and B). The infarct volume in the 
cerebral cortex and caudoputamen (CPu) showed inverse results (*p < 0.05, **p < 0.01 vs 
tMCAO-vehicle group; #p < 0.05, ##p < 0.01 tMCAO-tPA vs tMCAO-tPA+nPt group) (C). 
 
Figure 2. MMP-9 in vivo and ex vivo optical imaging 
     In vivo optical images of MMP at 48 hrs after tMCAO (A) with skull bone, (B) ex vivo 
optical imaging of whole brain, and (C) the coronal brain slice (upper panels for 
non-fluorescence pictures, and lower panels for pseudocolor images). Note the strong fluorescent 
signal in the right hemisphere reflecting the affected right MCA territory of tMCAO groups, the 
strongest in tMCAO-tPA group, and the great reduction by nPt treatment (A-C, lower panels). 
Macroscopic comparison of brain sections with TTC stain and ex vivo MMP image in identical 
tMCAO-tPA mice showed close colocalization of TTC stain defect (D, upper panel, white area) 
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and MMP image increase (D, lower panel, yellow area). Microscopic fluorescent observation 
confirmed the colocalization of endogenous MMPSense signals and exogenous MMP-9 antibody 
in the affected area (E). Bar indicates 50 μm. 
 
Figure 3. Gelatine zymography 
     Representative zymogram for MMP-9 at 48 hrs after tMCAO (A), and its densitometric 
analysis (B). Note the remarkable activation of MMP-9 in the ipsilateral hemisphere of the 
tMCAO-vehicle group compared with the sham control group (⋆p < 0.05), a significant 
aggravation in the tMCAO-tPA group (*p < 0.05), and a great reduction in nPt groups (*p < 0.05 
vs tMCAO-vehicle group, #p < 0.05 tMCAO-tPA vs tMCAO-tPA+nPt group).  
 
Figure 4. Immunohistochemistry 
     Representative photomicrographs for NAGO, occludin, collagen IV and MMP-9 
immunostaining of the peri-infarct areas of mouse brains in sham control, tMCAO-vehicle, 
tMCAO-tPA, tMCAO-tPA+nPt, and tMCAO-nPt groups. Bar indicates 50 μm. Quantitative 
analysis of the signal intensity compared to sham control are shown in the right, showing a 
significant decrease (collagen IV) and an increase (MMP-9) in the tMCAO-vehicle group, an 
aggravation in the tMCAO-tPA group, and an improvement by the nPt treatment (⋆p < 0.05, ⋆⋆p 
< 0.01 vs sham control; *p < 0.05, **p < 0.01 vs tMCAO-vehicle group; #p < 0.05, ##p < 0.01 
tMCAO-tPA vs tMCAO-tPA+nPt group).  
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Figure 5. Hydroethidine stain 
     Quantitative analysis of the ethidium signals in endothelium, neuron, astrocyte, and 
microglia of hydroethidine-stained coronal brain sections at 2 hrs after tMCAO (A) and 
representative fluorescent photomicrographs for hydroethidine, MAP2, CD31, and merged image 
of the peri-infarct areas of mouse brains. Bar indicates 10 μm (B). Note strong signals by 
hydroethidine in the endothelium of tMCAO-vehicle and tMCAO-tPA groups (filled arrows), 
and a much lower intensity by nPt treatment (open arrows) (B). ⋆p < 0.05, ⋆⋆p < 0.01 vs sham 
control; *p < 0.05, **p < 0.01 vs tMCAO-vehicle group; #p < 0.05 tMCAO-tPA vs 
tMCAO-tPA+nPt group. 





